Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

Phase 3

Conditions: Breast Cancer
Cardiac Toxicity
Perioperative/Postoperative Complications

First Posted Date: 2010-03-25

Last Posted Date: 2010-03-25

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 800

Registration Number: NCT01093235

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom

A Study in Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Cetuximab
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-Fluorouracil

First Posted Date: 2010-03-05

Last Posted Date: 2019-09-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 187

Registration Number: NCT01081041

Locations: 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico

Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: leucovorin calcium
Drug: fluorouracil
Drug: nelfinavir mesylate
Radiation: stereotactic body radiation therapy
Radiation: hypofractionated radiation therapy
Procedure: therapeutic conventional surgery

First Posted Date: 2010-02-12

Last Posted Date: 2023-10-10

Lead Sponsor: University of Nebraska

Target Recruit Count: 46

Registration Number: NCT01068327

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer

Phase 2

Completed

Conditions: Rectal Neoplasms

Interventions: Radiation: External beam radiation
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-FU
Drug: Capecitabine

First Posted Date: 2010-02-01

Last Posted Date: 2017-03-08

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 80

Registration Number: NCT01060007

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Phase 1

Completed

Conditions: Gastro-Intestinal Cancer

Interventions: Drug: 5-FU
Drug: Leucovorin
Drug: Irinotecan
Drug: Brivanib

First Posted Date: 2010-01-12

Last Posted Date: 2014-09-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT01046864

Locations: 🇺🇸
Scott & White Memorial Hospital And Clinic, Temple, Texas, United States
🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 1 locations

ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Trastuzumab
Drug: Fluorouracil
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2009-12-31

Last Posted Date: 2014-11-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 584

Registration Number: NCT01041404

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Panitumumab
Drug: Nab-paclitaxel
Drug: Carboplatin
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2009-12-21

Last Posted Date: 2023-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01036087

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)

Phase 3

Conditions: Breast Cancer

First Posted Date: 2009-12-14

Last Posted Date: 2013-08-02

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 800

Registration Number: NCT01031030

Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Radiation: External Beam Radiotherapy
Drug: Oxaliplatin
Drug: Fluorouracil
Drug: Leucovorin
Procedure: Surgical Resection

First Posted Date: 2009-11-16

Last Posted Date: 2017-07-12

Lead Sponsor: Trans Tasman Radiation Oncology Group

Target Recruit Count: 41

Registration Number: NCT01013805

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Phase 3

Active, not recruiting

Conditions: Pancreatic Adenocarcinoma
Stage II Pancreatic Cancer AJCC v6 and v7
Pancreatic Ductal Adenocarcinoma
Stage I Pancreatic Cancer AJCC v6 and v7
Pancreatic Intraductal Papillary-Mucinous Neoplasm

Interventions: Procedure: Biospecimen Collection
Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Chemotherapy
Drug: Erlotinib Hydrochloride
Procedure: Computed Tomography
Drug: Capecitabine
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Drug: Fluorouracil
Procedure: X-Ray Imaging
Radiation: Intensity-Modulated Radiation Therapy

First Posted Date: 2009-11-16

Last Posted Date: 2025-01-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 546

Registration Number: NCT01013649

Locations: 🇺🇸
Adena Regional Medical Center, Chillicothe, Ohio, United States
🇺🇸
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States
🇺🇸
Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States

and more 688 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy